Deloitte veteran is a board director of the company
Deloitte LLP (New York) has announced the appointment of Homi Kapadia, a 28-year veteran at the company, as leader of its life sciences industry practice, which employs nearly 4,000 professionals serving biopharma, med device and consumer health industries in the US. He takes over from Terry Hisey, principal, Deloitte Consulting LLP, who has transitioned to a top client-service position for the practice, according to a company statement.
Kapadia will guide the practice to deliver a "cross sector" viewpoint to clients in light of their growing interdependency on other sectors as the health system converges around population health and value-based incentives, says the statement. "We are moving to an era in which the growth and success of a life sciences company depends upon new relationships on the clinical delivery and payment sides, and upon having the right scale and level of capabilities globally," said Kapadia. "I look forward to working with our partners, principals and directors in drawing upon Deloitte's range of services and perspectives in giving executives at life sciences companies the confidence to chart a way forward in today's complex environment."
Kapadia, based in Philadelphia, has an MBA and an MS from the University of California, Los Angeles (UCLA), and a BTech from the Indian Institute of Technology, Bombay.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.